About 80% of patients with schizophrenia who received TEV-‘749 in the SOLARIS Phase 3 trial achieved clinical stabilization, according to post hoc data Teva presented this week, and that stabilization held across longer follow-up in the open-label extension. That number matters because stabilization is the threshold patients and clinicians actually care about in a maintenance setting, and it is harder to sustain than a statistically significant symptom score at week eight.
The SOLARIS trial tested TEV-‘749, a once-monthly subcutaneous formulation of olanzapine, in adults aged 18 to 64 with schizophrenia. The study ran an eight-week randomized, double-blind, placebo-controlled period before moving patients into an open-label extension where the durability data accumulated. The post hoc analyses Teva released this week also examined switching strategies, which tells you the commercial target: patients already on oral olanzapine or another antipsychotic who are candidates for a long-acting injectable but whose clinicians want a transition roadmap before committing.
The subcutaneous route is the design choice that separates TEV-‘749 from the existing olanzapine LAI on the market. Zyprexa Relprevv, approved in 2009, is an intramuscular formulation and carries a boxed warning for post-injection delirium sedation syndrome, a rare but serious reaction that required patients to be observed for at least three hours at a registered healthcare facility after each dose. A subcutaneous version without that post-injection monitoring requirement would meaningfully reduce the per-dose burden on clinics and patients. Whether TEV-‘749’s label will carry a similar restriction is the regulatory question Teva still needs to resolve, and the answer will determine whether the convenience argument holds in practice.
The once-monthly injectable market for schizophrenia is not empty: Uzedy, a subcutaneous risperidone formulation, received FDA approval in 2025, and paliperidone palmitate products have been established for years. Teva’s differentiation rests on olanzapine’s efficacy profile and on the switch-strategy data it is now putting in front of prescribers. The label language Teva secures, specifically whether post-injection monitoring is required, will be the single most consequential factor in how broadly TEV-‘749 gets adopted after approval.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
